The study investigates the structural dynamics of platelet glycoprotein VI (gpVI) and its interaction with SARS-CoV-2 receptor binding domain through the use of glenzocimab and two high-affinity monoclonal antibodies, 1d1 and 3d2. Glenzocimab demonstrates a mechanism that inhibits gpVI interactions essential for thrombus formation by causing dimerization loss and conformational changes. The antibody cocktail of 1d1 and 3d2 shows high efficacy against multiple SARS-CoV-2 variants, reducing viral load in treated subjects.